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A28 32  K32R (60%) 




158 A158S (70%) 





B12 211 203-212 
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BACKGROUND
Antiretroviral (ARV) drugs select 
characteristic ‘drug escape’ mutations 
in HIV sequence. Host HLA-restricted 
anti-HIV CTL responses also select 
escape mutations in HIV-1.
We hypothesised that;
-Selection effects (current and 
primordial) of drugs and CTL responses 
are evident at a population level.
-Drug resistance mutations should be 
drug-specific and CTL escape 
mutations should be specific for HLA 
class I alleles. 
-Drug pressure and CTL pressure may 
compete, leading to synergistic or 
antagonistic interactions. 
-Such interactions may help explain 
variable rates of emergence of drug 
resistance between individuals, 
discordance of drug resistance patterns 
in-vivo and in-vitro and 
genotype/phenotype discordance. 
METHODS
HIV-1 RT and protease (proviral DNA) 
sequencing in 492 subjects of the WA 
HIV Cohort, performed over 2303 
person-years of observation, were 
analysed.
Polymorphism(s) (versus consensus) of 
each single AA residue across the 
pooled viral sequences of the cohort  
were determined. 
We then carried out a multivariate 
analyses (logistic regression models 
using EpipopTM method) for each 
residue (eg 184 of RT) where;
outcome= specified polymorphism (eg 
M184V, M184x)
-covariates=ARV drugs and HLA-A &-B 
alleles present  in the population.
This process was repeated for all 
residues making up the full 
RT/protease proteins, giving a residue-
specific view of the independent & 
interactive selection effects in-vivo of 
host CTL and ARV drugs on HIV-1, at 
a population level. 
CONCLUSIONS
These findings support a highly dynamic, host-specific model of HIV-1 adaptation in-vivo, in which host CTL responses & ARV  therapy act as concurrent, 
competing or parallel interacting evolutionary forces at the level of single viral residues.
The selection of characteristic drug resistance mutations (& expected associations with their causative drugs) are evident at a population level.
The selection of characteristic CTL escape mutations is also evident at a population level, as HLA allele-specific polymorphisms. These are present in drug 
treated individuals.  
For 15 known drug resistance mutations in RT & protease, HLA alleles influence risk of having the mutation following drug therapy.   
Better understanding of CTL-driven effects on HIV evolution prove useful for individualisation of ARV therapy.  
RESULTS
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ZDV 3 <0.001 
D67N ZDV ZDV 10 <0.001 
K70R  thymidine 
NRTI 
ZDV 2 <0.001 
L74V ddI 
ABC 
ddI 8 <0.001 



















G190A/S nevirapine nevirapine 11 <0.001 
L210W ZDV ZDV 2  0.016 
T215 Y thymidine 
NRTI  
ZDV 4 <0.001 
K219Q/E ZDV ZDV 4 <0.001 
 
Map of HIV-1 RT; HLA & drug associated polymorphisms
HLA allele-specific polymorphisms have characteristic AA substitution(s)Map of HIV-1 protease; HLA & drug associated polymorphisms 
Interactions between HLA alleles and ARV drugs
Particular HLA alleles independently increased the odds of; 
(RT) M41L, K70R, Y181C/I,G190A/S, T210W, T215Y/F 
( protease) L10I/R, M46I/L, A71V/T, 73,V77I,V82A/T/F,I84V, N88S, L90M
e.g. Of all ZDV-treated individuals (n=225),
Prevalence of HLA-A28 in-total cohort   M41L +    M41- RR (of M41L on ZDV if HLA-28) 
8%              16%        5%     3.9, p=0.005 (Fisher’s exact test).  
Other +ve interactions; RT                              protease
total cohort    K70R+      K70R total cohort I84V+      I84V-
A10     2%                17%          8% A9      22%   50%       15%
Y181C/I+  Y181C/I- N88S+    N88S-
B8      23%               47% 20%               B15    18%               64%       17%
G190A/S+  G190A/S-
B8      23%                64%         20%
HLA alleles reduced the odds of;RT- K103N, M184V and in protease- L10I/R/Vl
HLA allele  S ite(s) o f allele- 
associated   




am ino acid 
substitution(s) (%) 
B7 10 L10I (73% ) 
B12 35 E12D  (94% ) 
B13 62 I62V (82% ) 
 65 E65D  (60% ) 
 90 L90M  (67% ) 
 93 I93L (93% ) 
B37 35 E35D  (100% ) 
 37 N37D (57% ) 






Selection of drug resistance mutations is evident at a 
population level
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ABSTRACT
Background:Antiretroviral treatment (ART) induced mutations in HIV-1 
reverse transcriptase (RT) and protease that allow viral escape from 
drug suppression are well characterised. Similarly, host CTL responses 
select viral variants that can escape CTL responses. We have shown in 
a large population study, that CTL escape mutations are evident as HLA 
allele-specific mutations. We examined the hypothesis that selection 
pressures of both host HLA-restricted CTL responses and ART interact 
at specific sites, causing variable susceptibility to drug resistance 
mutation between HLA diverse individuals. Methods:492 subjects with 
antiretroviral drug exposure, HLA-A and -B typing, pre- and post-ART 
RT(20-228) and protease(1-99) sequences over 2303 patient-years 
were studied. Multivariate logistic regression models were used to 
analyse associations between the development of ART resistance 
mutations (as the outcomes) and ART (as covariates). We then 
analysed the effects of HLA alleles in these models. 
Results:Associations between ZDV, 3TC, ddI, ddC, ABC, NVP, EFV, 
IDV, RTV, SQV, NFV and one or more of their corresponding, known
primary and secondary drug resistance mutations were demonstrable 
using this population-based approach [eg.M184V in RT, was associated 
with use of 3TC(OR=69,p<0.001) and L90M
in protease was associated with use of NFV (OR=3.1,p=0.003)]. At other 
sites (46 RT and 12 protease residues) drug exposures decreased risk 
of mutation. In models incorporating HLA alleles, there were 57 residues 
in RT and 33 in protease at which mutation was associated with specific 
HLA-A and –B alleles (p<0.05). Like drug resistance mutations, HLA-
specific mutations (putative CTL escape mutations) were site-specific, 
associated with stereotypic amino acid substitutions and secondary 
mutations. At 8 RT and 7 protease drug mutation sites, we detected 
HLA associations independently increasing or decreasing the risk of 
mutation [eg,T215Y in RT was associated with ZDV(OR=3.7,p<0.001)
and HLA-B7(OR=2.3,p=0.007), but was less likely in
those with HLA-B13(OR=0.2,p=0.03)]. In protease, V82A/T/F was 
associated with IDV(OR=4.3, p<0.001) and HLA-A2 (OR=5.4, p=0.002). 
Conclusions:Knowledge of characteristic HLA-specific effects on viral 
sequence, including on drug resistance mutations may help explain 
variable susceptibility to drug resistance and be useful for 
individualisation of HIV therapy.
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D30N nelfinavir ND   
M46I/L  primary 
indinavir 
indinavir 3  0.006 
G48V primary 
saquinavir 
ND   




























I84V indinavir indinavir 6 <0.001 
N88S nelfinavir nelfinavir 11 <0.001 
L90M saquinavir 
nelfinavir 
saquinavir 
nelfinavir 
2 
9 
0.012 
<0.001 
 
